Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

North America Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026

Published by KBV Research Product code 988514
Published Content info 88 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026
Published: January 29, 2021 Content info: 88 Pages
Description

The North America Antibiotics Market would witness market growth of 4.6% CAGR during the forecast period (2020-2026).

Antibiotics are the combination of medicines that are used to cure an infection caused by germs-bacteria and some parasites, by restricting the growth of microorganisms or destroying them. These antibiotics are also called antibacterial or antimicrobials. With the discovery of the antibiotic penicillin in 1920, many antibiotic compounds have been utilized to cure various bacterial infections. Growing incidents of chronic and infectious diseases in the world and the effectiveness of antibiotics to cure a broad spectrum of bacterial infections have resulted in the swift growth of the antibiotics market.

The development of unique approaches for advanced antibiotics for curing bacterial infections and numerous clinical trials drives the global antibiotics market. Moreover, the rising rates of infectious diseases like pneumonia, tuberculosis, HIV/AIDS, and malaria will boost the market. Following this, the increasing gap in the demand and supply of antibiotics also propel the market growth. Huge investments in research and development by biotech companies are estimated to increase the global antibiotics market.

Furthermore, favorable government regulations like the Generating Antibiotics Incentives Now (GAIN) Act provide a push to research and development processes, offering various opportunities for key companies. Although, the indiscriminate and sustained utilization of antibiotics in the last few years has helped in the development of antibiotic-resistant bacteria and pathogens. There are some infections like pneumonia; gonorrhea and tuberculosis that were initially susceptible to antibiotics have become resistant to these drugs. However, the market is estimated to observe remarkable growth because of the development of advanced molecules and novel combination therapies to cure antibiotic-resistant microbial infections.

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Scope of the Study

Market Segments covered in the Report:

By Action Mechanism

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors,
  • Mycolic Acid Inhibitors

By Drug Class

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenem
  • Aminoglycosides
  • Sulfonamides,
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled

  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Antibiotics Market, by Action Mechanism
    • 1.4.2 North America Antibiotics Market, by Drug Class
    • 1.4.3 North America Antibiotics Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Approvals
    • 3.2.4 Acquisition and Mergers
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct - 2020, Jul) Leading Players

Chapter 4. North America Antibiotics Market by Action Mechanism

  • 4.1 North America Cell Wall Synthesis Inhibitors Market by Country
  • 4.2 North America Protein Synthesis Inhibitors Market by Country
  • 4.3 North America DNA Synthesis Inhibitors Market by Country
  • 4.4 North America RNA Synthesis Inhibitors Market by Country
  • 4.5 North America Mycolic Acid Inhibitors Market by Country

Chapter 5. North America Antibiotics Market by Drug Class

  • 5.1 North America Cephalosporin Market by Country
  • 5.2 North America Penicillin Market by Country
  • 5.3 North America Fluoroquinolone Market by Country
  • 5.4 North America Macrolides Market by Country
  • 5.5 North America Carbapenem Market by Country
  • 5.6 North America Aminoglycosides Market by Country
  • 5.7 North America Sulfonamides Market by Country
  • 5.8 North America Others Market by Country

Chapter 6. North America Antibiotics Market by Country

  • 6.1 US Antibiotics Market
    • 6.1.1 US Antibiotics Market by Action Mechanism
    • 6.1.2 US Antibiotics Market by Drug Class
  • 6.2 Canada Antibiotics Market
    • 6.2.1 Canada Antibiotics Market by Action Mechanism
    • 6.2.2 Canada Antibiotics Market by Drug Class
  • 6.3 Mexico Antibiotics Market
    • 6.3.1 Mexico Antibiotics Market by Action Mechanism
    • 6.3.2 Mexico Antibiotics Market by Drug Class
  • 6.4 Rest of North America Antibiotics Market
    • 6.4.1 Rest of North America Antibiotics Market by Action Mechanism
    • 6.4.2 Rest of North America Antibiotics Market by Drug Class

Chapter 7. Company Profiles

  • 7.1 GlaxoSmithKline PLC (GSK)
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Johnson and Johnson
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental &Regional Analysis
    • 7.2.4 Research & Development Expenses
    • 7.2.5 Recent strategies and developments:
      • 7.2.5.1 Acquisition and Mergers:
  • 7.3 Merck & Co., Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.1 Recent strategies and developments:
      • 7.3.1.1 Product Launches and Product Expansions:
      • 7.3.1.2 Approvals:
  • 7.4 Pfizer, Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Recent strategies and developments:
      • 7.4.4.1 Acquisition and Mergers:
      • 7.4.4.2 Product Launches and Product Expansions:
  • 7.5 Bayer AG
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
  • 7.6 Novartis AG
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Segmental and Regional Analysis
    • 7.6.4 Recent strategies and developments:
      • 7.6.4.1 Partnerships, Collaborations, and Agreements:
  • 7.7 Sanofi S.A.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 Recent strategies and developments:
      • 7.7.5.1 Acquisition and Mergers:
      • 7.7.5.2 Partnerships, Collaborations, and Agreements:
  • 7.8 Abbott Laboratories
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 F. Hoffmann-La Roche Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Segmental and Regional Analysis
    • 7.9.4 Research & Development Expense
    • 7.9.5 Recent strategies and developments:
      • 7.9.5.1 Partnerships, Collaborations, and Agreements:
  • 7.10. Eli Lilly and Company
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Regional Analysis
    • 7.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 North America Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 2 North America Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Antibiotics Market
  • TABLE 4 Product Launches And Product Expansions- Antibiotics Market
  • TABLE 5 Approvals- Antibiotics Market
  • TABLE 6 Acquisition and Mergers- Antibiotics Market
  • TABLE 7 North America Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 8 North America Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 9 North America Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 10 North America Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 11 North America Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 12 North America Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 13 North America DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 14 North America DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 15 North America RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 16 North America RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 17 North America Mycolic Acid Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 18 North America Mycolic Acid Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 19 North America Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 20 North America Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 21 North America Cephalosporin Market by Country, 2016 - 2019, USD Million
  • TABLE 22 North America Cephalosporin Market by Country, 2020 - 2026, USD Million
  • TABLE 23 North America Penicillin Market by Country, 2016 - 2019, USD Million
  • TABLE 24 North America Penicillin Market by Country, 2020 - 2026, USD Million
  • TABLE 25 North America Fluoroquinolone Market by Country, 2016 - 2019, USD Million
  • TABLE 26 North America Fluoroquinolone Market by Country, 2020 - 2026, USD Million
  • TABLE 27 North America Macrolides Market by Country, 2016 - 2019, USD Million
  • TABLE 28 North America Macrolides Market by Country, 2020 - 2026, USD Million
  • TABLE 29 North America Carbapenem Market by Country, 2016 - 2019, USD Million
  • TABLE 30 North America Carbapenem Market by Country, 2020 - 2026, USD Million
  • TABLE 31 North America Aminoglycosides Market by Country, 2016 - 2019, USD Million
  • TABLE 32 North America Aminoglycosides Market by Country, 2020 - 2026, USD Million
  • TABLE 33 North America Sulfonamides Market by Country, 2016 - 2019, USD Million
  • TABLE 34 North America Sulfonamides Market by Country, 2020 - 2026, USD Million
  • TABLE 35 North America Others Market by Country, 2016 - 2019, USD Million
  • TABLE 36 North America Others Market by Country, 2020 - 2026, USD Million
  • TABLE 37 North America Antibiotics Market by Country, 2016 - 2019, USD Million
  • TABLE 38 North America Antibiotics Market by Country, 2020 - 2026, USD Million
  • TABLE 39 US Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 40 US Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 41 US Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 42 US Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 43 US Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 44 US Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 45 Canada Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 46 Canada Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 47 Canada Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 48 Canada Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 49 Canada Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 50 Canada Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 51 Mexico Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 52 Mexico Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 53 Mexico Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 54 Mexico Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 55 Mexico Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 56 Mexico Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 57 Rest of North America Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 58 Rest of North America Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 59 Rest of North America Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 60 Rest of North America Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 61 Rest of North America Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 62 Rest of North America Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 63 Key Information - GlaxoSmithKline PLC (GSK)
  • TABLE 64 Key information -Johnson and Johnson
  • TABLE 65 key information - Merck & Co., Inc.
  • TABLE 66 Key Information - Pfizer, Inc.
  • TABLE 67 Key Information - Bayer AG
  • TABLE 68 Key Information - Novartis AG
  • TABLE 69 Key Information - Sanofi S.A.
  • TABLE 70 Key Information - Abbott Laboratories
  • TABLE 71 key information - F. Hoffmann-La Roche Ltd.
  • TABLE 72 Key Information - Eli Lilly and Company

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
  • FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct - 2020, Jul) Leading Players
  • FIG 5 Recent strategies and developments: Merck & Co., Inc.
  • FIG 6 Recent strategies and developments: Pfizer, Inc.
  • FIG 7 Recent strategies and developments: Sanofi S.A.
Back to Top